B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) on Monday, setting a price target of $37, which is approximately 115.24% above the present share price of $17.19.
Mamtani expects TG Therapeutics to post earnings per share (EPS) of -$0.48 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in TG Therapeutics, with an average price target of $41.
The analysts price targets range from a high of $60 to a low of $32.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $38 thousand and a net profit of -$50.25 million. The company's market cap is $1.97 billion.
According to TipRanks.com, B.Riley FBR analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 12.2% and a 45.70% success rate.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.